ReviewInternational journal of molecular sciences2022
Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Imaging markers of cerebral small vessel disease are associated with Alzheimer's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2025Pooled it
- New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Review
- Decreased Plasma IGF-1 Is Associated with Cortical Atrophy, but Not Concomitant Cerebrovascular Disease in Alzheimer's Dementia.Biomolecules · 2026Article
- Clinical and neuroimaging correlates of motoric cognitive risk syndrome in cerebral small vessel disease: a cross-sectional study.Frontiers in aging neuroscience · 2026Article
- Hypertension and Cerebral Small Vessel Disease: A Review of the Pathophysiology, Progression, and Prevention.Cureus · 2025Review
- Integrating visual assessments and quantification methods for tau PET staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Dementia from Small Vessel Disease Versus Alzheimer's Disease: Separate Diseases or Distinct Manifestations of Cerebral Capillopathy Due to Blood-Brain Barrier Dysfunction? A Pilot Study.International journal of molecular sciences · 2025Article
- WMH Contributions to Cognitive Impairment: Rationale and Design of the Diverse VCID Study.Stroke · 2025Review
- MRI-derived global small vessel disease burden serves as a marker of hippocampal sclerosis and clinical stage across the probable Alzheimer's disease continuum.Frontiers in aging neuroscience · 2025Article
- Roles of neuroimaging markers and biomarkers in cerebral small vessel disease and their associations with cognitive function.Frontiers in neurology · 2025Review
- Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Investigating ocular biomarkers and differential diagnosis of Alzheimer's disease and vascular cognitive impairment based on multimodal imaging.Journal of biomedical optics · 2024Article
- Longitudinal evidence for a mutually reinforcing relationship between white matter hyperintensities and cortical thickness in cognitively unimpaired older adults.Alzheimer's research & therapy · 2024Article
- Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.Neurology · 2024Article
- Association of hemoglobin with plasma neurofilament light and white matter hyperintensities in Alzheimer's disease continuum.Heliyon · 2024Article
- Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Distinct effects of blood pressure parameters on Alzheimer's and vascular markers in 1,952 Asian individuals without dementia.Alzheimer's research & therapy · 2024Article
- Article
- Serum Brevican as a Biomarker of Cerebrovascular Disease in an Elderly Cognitively Impaired Cohort.Biomolecules · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) is characterized by the presence of β-amyloid (Aβ) and tau, and subcortical vascular cognitive impairment (SVCI) is characterized by cerebral small vessel disease (CSVD). They are the most common causes of cognitive impairment in the elderly population. Concurrent CSVD burden is more commonly observed in AD-type dementia than in other neurodegenerative diseases. Recent developments in Aβ and tau positron emission tomography (PET) have enabled the investigation of the relationship between AD biomarkers and CSVD in vivo. In this review, we focus on the interaction between AD and CSVD markers and the clinical effects of these two markers based on molecular imaging studies. First, we cover the frequency of AD imaging markers, including Aβ and tau, in patients with SVCI. Second, we discuss the relationship between AD and CSVD markers and the potential distinct pathobiology of AD markers in SVCI compared to AD-type dementia. Next, we discuss the clinical effects of AD and CSVD markers in SVCI, and hemorrhagic markers in cerebral amyloid angiopathy. Finally, this review provides both the current challenges and future perspectives for SVCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.